MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, opened the second phase of its new €29 million biologics testing center in China, adding 1,500 square meters to the lab that opened last year.  These are the first biosafety laboratories for the company in this market, enabling clients to locally access a broad range of testing services for cell line characterization and lot release from preclinical development to commercialization. The first phase of investment provides...